The effect of text message support on diabetes self-management in developing countries – A randomised trial

Josefien Van Olmen*, Guy Kegels, Catherine Korachais, Jeroen de Man, Kristien Van Acker, Jean Clovis Kalobu, Maurits van Pelt, Grace Marie Ku, Heang Hen, Dominique Kanda, Billy Malombo, Christian Darras, François Schellevis

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objective mHealth interventions have the potential to facilitate self-management. This TEXT4DSM study implemented a mobile phone intervention in existing diabetes programmes in three low- and middle-income countries (Democratic Republic of Congo, Cambodia, and the Philippines). Research design and methods Sub-studies with a similar randomised controlled trial design were conducted in three different countries. Each sub-study included 480 adults with diabetes. Subjects were randomised to receive either routine care or routine care plus text message self-management support. The primary outcome was the difference in the proportion of subjects with well-controlled diabetes after 2 years. Results Baseline and 2-year HbA1c measurements were available for 781 individuals. After 2 years, the proportion of subjects with controlled HbA1c was 2.8% higher in the intervention group than in the control group (difference not statistically significant). In the logistic regression model, the odds ratio for having controlled diabetes after the intervention was 1.1, after adjusting for baseline HbA1c level, sex, receiving insulin treatment, and participating in the routine programme. The HbA1c dynamics over time differed between programmes; the number of people with controlled diabetes tended to increase in DR Congo and decrease in Cambodia. Conclusion This study was the first to test the same mHealth intervention in different countries. The finding that text messages did not show an additional effect on diabetes control implied that expectations about mHealth should be cautious. The degree of coverage, the quality of the routine programme, and the progression of disease can interfere with the expected impact. Trial registration: ISRCTN registry (86247213).

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalJournal of Clinical and Translational Endocrinology
Volume7
DOIs
Publication statusPublished - 1 Mar 2017

Cite this